Onconetix Provides Additional Strategic Bridge Financing to Realbotix LLC in Continued Support of Pending Acquisition
Bridge advances reduce cash required at closing by the principal advanced plus an additional $500,000.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Onconetix (ONCO) advanced another $500,000 to Realbotix LLC under a bridge financing facility supporting its pending acquisition of the company. Total principal outstanding is now $3,000,000 under the facility, which permits aggregate loans of up to $5,000,000.
The facility bears no interest before the Share Exchange Agreement closes. At closing, the note and all obligations under it will be automatically cancelled and discharged. Cash required at closing will be reduced by total principal advanced plus an additional $500,000. If the agreement is terminated, interest accrues at 12% per annum from termination.
Onconetix agreed to acquire 100% of Realbotix’s equity in an all-stock transaction. Closing remains subject to Onconetix shareholder approval, required regulatory approvals and other conditions. The combined company is expected to trade on Nasdaq after closing.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major point. Forward-looking: it has not happened yet and may not happen.Closing cash requirements will fall by total principal advanced plus an additional $500,000. 23% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.The pending acquisition would give Onconetix 100% of Realbotix’s equity.
- Minor point. Forward-looking: it has not happened yet and may not happen.Agreement termination triggers 12% annual interest on the bridge financing from the termination date.
Negative
- Major pointThe additional $500,000 advance brings Onconetix’s outstanding lending to Realbotix to $3,000,000. 23% of market cap
- Moderate point. Forward-looking: it has not happened yet and may not happen.The acquisition’s all-stock consideration would dilute existing shareholders.
- Minor point. Forward-looking: it has not happened yet and may not happen.Bridge financing earns no interest before closing; the note and its obligations are discharged at closing.
- Minor pointClosing remains subject to Onconetix shareholder approval and required regulatory approvals, alongside other conditions.
Details
Market Reaction – ONCO
On Oct 23, the day this news came out, the latest delayed price for ONCO is 2.83% above the previous close. Our momentum scanner has recorded 2 alerts for this stock so far that day. The latest delayed price is $0.42. Relative volume is very high at 4.0x the average.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Gold for real-time data.
Key Figures
- Additional advance
- $500,000
- New advance under the Grid Note
- Principal outstanding
- $3,000,000
- Total drawn under the facility after this advance
- Facility limit
- $5,000,000
- Aggregate loans available under the Grid Note
- Termination interest
- 12% per annum
- Accrues from the date the Share Exchange Agreement is terminated
- Additional closing cash reduction
- $500,000
- Additional reduction beyond the total principal advanced, upon closing
Previous Acquisition Reports
-
Established the same facility's $5 million cap, $2.5 million initial advance, and contingent termination interest.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
form 8-k regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Additional
Total Drawn Under Facility Now
CINCINNATI, Ohio, Oct. 23, 2026 (GLOBE NEWSWIRE) -- Onconetix, Inc. (Nasdaq: ONCO) (“Onconetix” or the “Company”) today announced that it has made an additional advance of
As previously disclosed, the Grid Note provides for aggregate loans of up to
A description of the additional advance is included in Onconetix’s Current Report on Form 8-K filed with the SEC on October 23, 2026. The full text of the Note is available at www.sec.gov.
As previously announced on February 12, 2026, Onconetix entered into the Share Exchange Agreement to acquire
This communication is being provided for informational purposes only. Investors are cautioned not to place undue reliance on forward-looking or projected information.
About Onconetix, Inc.
Onconetix, Inc. (Nasdaq: ONCO) is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative oncology solutions. Onconetix owns Proclarix®, an in vitro diagnostic test for prostate cancer originally developed by Proteomedix and approved for sale in the European Union under the IVDR, which it anticipates will be marketed in the U.S. as a lab developed test through its license agreement with Labcorp. For more information, visit www.onconetix.com.
About Realbotix LLC
Realbotix LLC is a wholly-owned subsidiary of Realbotix Corp. (TSX-V: XBOT; Frankfurt: 76M0.F; OTC: XBOTF) and the target of Onconetix’s pending acquisition. Realbotix LLC develops AI-powered humanoid robots designed for human interaction across enterprise and consumer environments. Manufactured in the United States, Realbotix’s patented AI and robotics technologies enable lifelike expressions, motion, vision, and social engagement. For more information, visit www.realbotix.ai.
Additional Information and Where to Find It
In connection with the proposed transaction between Realbotix and Onconetix, Onconetix intends to file with the SEC a Registration Statement on Form S-4 (the “Registration Statement”) to register the common stock to be issued by Onconetix in connection with the proposed transaction. The Registration Statement will include a proxy statement of Onconetix and a prospectus of Onconetix (the “Proxy Statement/Prospectus”), and each of Realbotix and Onconetix may file with the SEC other relevant documents concerning the proposed transaction. After the Registration Statement is declared effective, the definitive Proxy Statement/Prospectus will be sent to the stockholders of Onconetix to seek their approval of the proposed transaction. This is not a substitute for the Registration Statement, the Proxy Statement/Prospectus or any other relevant documents that Realbotix or Onconetix has filed or will file with the SEC. BEFORE MAKING ANY VOTING OR INVESTMENT DECISION, INVESTORS AND STOCKHOLDERS OF ONCONETIX ARE URGED TO CAREFULLY AND ENTIRELY READ THE REGISTRATION STATEMENT AND PROXY STATEMENT/PROSPECTUS REGARDING THE PROPOSED TRANSACTION AND ANY OTHER RELEVANT DOCUMENTS, AS WELL AS ANY AMENDMENTS OR SUPPLEMENTS TO THOSE DOCUMENTS, IF AND WHEN THEY BECOME AVAILABLE, BECAUSE THEY WILL CONTAIN IMPORTANT INFORMATION ABOUT REALBOTIX, ONCONETIX, THE PROPOSED TRANSACTION, AND RELATED MATTERS.
A copy of the Registration Statement, Proxy Statement/Prospectus, as well as other relevant documents filed by Realbotix and Onconetix with the SEC, may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov. The information on Realbotix or Onconetix’s respective websites is not, and shall not be deemed to be, a part of this communication or incorporated into other filings either company makes with the SEC.
Participants in the Solicitation
Realbotix, Onconetix and certain of their respective directors, executive officers, and employees may be deemed to be participants in the solicitation of proxies in connection with the proposed transaction. Information about the directors and executive officers of Onconetix, their ownership of Onconetix common stock, and Onconetix’s transactions with related persons is set forth in the 10-K, as filed with the SEC on March 13, 2026, and other documents that may be filed from time to time with the SEC. Additional information about the directors and executive officers of Realbotix and Onconetix and other persons who may be deemed to be participants in the solicitation of stockholders of Onconetix in connection with the proposed transaction and a description of their direct and indirect interests will be included in the Proxy Statement/Prospectus related to the proposed transaction or other relevant materials, which will be filed with the SEC. These documents may be obtained free of charge, when they become available, at the SEC’s website at www.sec.gov and from Onconetix using the sources indicated above.
No Offer or Solicitation
This communication is for informational purposes only and is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy or sell any securities or the solicitation of any proxy, vote or approval, nor shall there be any sale of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. No offer of securities shall be made except by means of a prospectus meeting the requirements of Section 10 of the Securities Act, or in a transaction exempt from the registration requirements of the Securities Act.
Forward-Looking Statements
Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimate,” “expect,” and “intend,” among others. These forward-looking statements (including, without limitation, the anticipated benefits and opportunities that may be generated by the proposed transaction described herein) are based on Onconetix’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, the occurrence of any event, change, or other circumstances that could give rise to the right of one or both of the parties to terminate the share exchange agreement; the possibility that the proposed transaction does not close when expected or at all because the conditions to closing are not satisfied on a timely basis or at all, including the failure to timely obtain stockholder approval for the proposed transaction from Onconetix’s stockholders, if at all; risks related to Onconetix’s continued listing on Nasdaq until closing of the proposed transaction; the outcome of any legal proceedings that may be instituted against Realbotix, Onconetix, or the combined company; the possibility that the anticipated benefits of the proposed transaction are not realized when expected or at all; the possibility that the vision, goals, and trajectory of the combined company are not timely achieved or realized or achieved or realized at all; the possibility that the proposed transaction may be more expensive or take longer to complete than anticipated, including as a result of unexpected factors or events; the diversion of management’s attention from ongoing business operations and opportunities; changes in Onconetix’s stock price before closing; and other factors that may affect future results of Realbotix, Onconetix, or the combined company. Onconetix does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Onconetix’s Annual Report on Form 10-K filed with the SEC on March 13, 2026 (the “10-K”) and periodic reports filed with the SEC on or after the date thereof. All of Onconetix’s forward-looking statements are expressly qualified by all such risk factors and other cautionary statements. The information set forth herein speaks only as of the date thereof.
Investor and Media Contact:
Onconetix, Inc.
201 E. Fifth Street, Suite 1900
Cincinnati, OH 45202
Phone: (513) 620-4101
Email: investors@onconetix.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
How much bridge financing has Onconetix provided to Realbotix?
Onconetix has advanced $3,000,000 in total principal, including the latest $500,000 advance. The facility permits aggregate loans of up to $5,000,000.
What happens to Onconetix’s Realbotix bridge loan if the acquisition closes or is terminated?
At closing, the note and all obligations under it are automatically cancelled and discharged in full; if the agreement is terminated, interest accrues at 12% per annum from termination. Cash required at closing is reduced by total principal advanced plus an additional $500,000.